secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2023-09-21T23:59:59+00:00
Accession:  0000950170-23-049044
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar licenses zetomipzomib to Everest for up to $132.5M in Greater China & SE Asia
--------------------------------------------------------------------------------

- Kezar receives $7.0M upfront; eligible for up to $132.5M in development, regulatory & commercial milestones.
- Everest gets exclusive rights to develop and commercialize zetomipzomib for non-oncology uses in Greater China, South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam, Philippines.
- Parties will collaborate on PALIZADE Phase 2b lupus nephritis trial; Everest contributes local expertise and covers costs in licensed territories.
- Tiered royalties from single-digit to low-teens on net sales; Kezar supplies drug with Everest option to manufacture after PALIZADE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023049044/0000950170-23-049044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023049044/kzr-20230920.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-049044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer